Clinical trials: Non-Small Cell Lung
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.
Non Small Cell Lung Cancer
Phase I Combination Ixabepilone + Cisplatin
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the…
- Trial name
- NCT00832117
- Testing
- Ixabepilone, Cisplatin
- Where
- 7 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- R-Pharm
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort…
- Conditions
- Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma
- Trial name
- TRAP (NCT02029690)
- Testing
- ADI-PEG 20
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 85 people
- Sponsor
- Polaris Group
Non-Small Cell Lung Cancer
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a Phase 2, multicenter study designed to evaluate the efficacy and safety of trastuzumab emtansine administered as a single-agent in participants with HER2-positive (HER2 IHC 2+ or HER2 IHC 3+) advanced or metastatic…
- Trial name
- NCT02289833
- Testing
- Trastuzumab Emtansine
- Where
- 23 sites in United States, Germany and 5 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Small-cell Lung Cancer
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease…
- Trial name
- NCT06789796
- Testing
- Iparomlimab and Tuvonralimab (QL1706), QL1604
- Volunteers
- 636 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
The purpose of this study is to evaluate the efficacy and safety of olmutinib 600 mg QD in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase…
- Trial name
- NCT04510415
- Testing
- Olmutinib
- Where
- 8 sites in South Korea
- Volunteers
- 2 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Lung Cancer
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
This is a phase I/II, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS111 for patients with Non-small cell lung cance.
- Trial name
- NCT04993391
- Testing
- JS111(AP-L1898 Capsules)
- Where
- 37 sites in China
- Volunteers
- 32 people
- Sponsor
- Suzhou Junjing BioSciences Co., Ltd.
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680). This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy…
- Trial name
- NCT03950674
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
A Study of LY4175408 in Participants With Advanced Cancer
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
- Trial name
- NCT07046923
- Testing
- LY4175408, Pembrolizumab, Carboplatin
- Where
- 27 sites in United States, China and 4 more
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer
TLK199.2102 was a multicenter Phase 2 randomized study to determine the effect of Telintra treatment on chemotherapy induced neutropenia (CIN) in patients with non small cell lung cancer receiving first-line therapy with…
- Trial name
- NCT00701870
- Testing
- ezatiostat hydrochloride (Telintra®)
- Where
- 24 sites in United States
- Volunteers
- 1 people
- Sponsor
- Telik
Lung Cancer
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030641
- Testing
- oblimersen sodium, docetaxel
- Where
- 44 sites in United States, Canada and 1 more
- Sponsor
- Genta Incorporated
Non-small Cell Lung Cancer, Head and Neck Cancer
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03518554
- Testing
- JAB-3068
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
Evaluate molecular testing and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs.
- Trial name
- PANORAMRETRO (NCT03721289)
- Where
- 10 sites in Argentina, Chile and 2 more
- Volunteers
- 463 people
- Sponsor
- AstraZeneca
NSCLC
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with…
- Trial name
- NCT05693090
- Testing
- Tipifarnib, Osimertinib
- Where
- 2 sites in United States
- Sponsor
- Kura Oncology, Inc.
Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II
Oncoxin® and Quality of Life in Cancer Patients
It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain high relative dose intensity of anticancer treatments.
- Conditions
- Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Gastric Cancer Stage III
- Trial name
- NCT03550482
- Testing
- ONCOXIN®
- Where
- 9 sites in Kazakhstan, Russia
- Volunteers
- 133 people
- Sponsor
- Catalysis SL
Advanced or Metastatic NSCLC
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
This is a randomized, controlled, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of oral HS-10504 monotherapy versus platinum-based doublet chemotherapy in participants with locally…
- Trial name
- NCT07754123
- Testing
- HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin)
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system.
- Trial name
- NCT00132379
- Testing
- ABR-217620, docetaxel
- Where
- 4 sites in United States, Denmark and 1 more
- Volunteers
- 13 people
- Sponsor
- Active Biotech AB
Advanced Non-small Cell Lung Cancer
Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic NSCLC as a phase II trial
- Trial name
- NCT03693547
- Testing
- utidelone injection
- Where
- 4 sites in China
- Volunteers
- 26 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Nonsmall Cell Lung Cancer, NSCLC
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following…
- Trial name
- NCT02973789
- Testing
- NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
- Where
- 124 sites in United States, Austria and 16 more
- Volunteers
- 291 people
- Sponsor
- NovoCure GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.